Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes

European Journal of Pharmacology

Volumn 563, Issue 1-3, 2007, Pages 61-68

  Liu, Hui ^a,b   Jin, Man Wen ^b   Xiang, Ji Zhou ^b   Huang, Yu ^c   Sun, Hai Ying ^a   Chiu, Shui Wha ^d   Lau, Chu Pak ^a   Li, Gui Rong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Human atrium; Raloxifene; Transient outward potassium current; Ultra rapid delayed rectifier potassium current

Indexed keywords

DELAYED RECTIFIER POTASSIUM CHANNEL; ESTRADIOL; FULVESTRANT; POTASSIUM; RALOXIFENE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HEART ATRIUM; HEART ATRIUM MUSCLE; HEART MUSCLE CELL; HEART REPOLARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; INHIBITION KINETICS; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; REPOLARIZATION; STEADY STATE; WHOLE CELL;

ACTION POTENTIALS; CELLS, CULTURED; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; HEART ATRIA; HUMANS; MIDDLE AGED; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 34247113320     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.072     Document Type: Article

References (28)

1. Courtemanche M., Ramirez R.J., and Nattel S. Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am. J. Physiol. 275 (1998) H301-H321
2. Courtemanche M., Ramirez R.J., and Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. 42 (1999) 477-489
3. Du X.L., Lau C.P., Chiu S.W., Tse H.F., Gerlach U., and Li G.R. Effects of chromanol 293B on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes. J. Mol. Cell. Cardiol. 35 (2003) 293-300
4. Dukes I.D., Cleemann L., and Morad M. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J. Pharmacol. Exp. Ther. 254 (1990) 560-569
5. Feng J., Wang Z., Li G.R., and Nattel S. Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J. Pharmacol. Exp. Ther. 281 (1997) 384-392
6. Figtree G.A., Lu Y., Webb C.M., and Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100 (1999) 1095-1101
7. + current by verapamil in human atrial myocytes. J. Mol. Cell. Cardiol. 36 (2004) 257-26
8. to in human and rabbit atrial myocytes. Am. J. Physiol. 269 (1995) H463-H472
9. + current in human ventricular myocytes. Circ. Res. 78 (1996) 689-696
10. Li G.R., Feng J., Yue L., and Carrier M. Transmural heterogeneity of action potentials and Ito1 in myocytes isolated from the human right ventricle. Am. J. Physiol. 275 (1998) H369-H377
11. Li G.R., Zhang M., Satin L.S., and Baumgarten C.M. Biphasic effects of cell volume on excitation-contraction coupling in rabbit ventricular myocytes. Am. J. Physiol. 282 (2002) H1270-H1277
12. Liew R., Stagg M.A., MacLeod K.T., and Collins P. Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current. Br. J. Pharmacol. 142 (2004) 89-96
13. Mori-Abe A., Tsutsumi S., Takahashi K., Toya M., Yoshida M., Du B., Kawagoe J., Nakahara K., Takahashi T., Ohmichi M., and Kurachi H. Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J. Endocrinol. 178 (2003) 417-426
14. Moritz A., Radtke O.A., Gust R., Glusa E., and Pertz H.H. Characterisation of the relaxant response to raloxifene in porcine coronary arteries. Eur. J. Pharmacol. 545 (2006) 153-160
15. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
16. Nattel S., Yue L., and Wang Z. Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cell. Physiol. Biochem. 9 (1999) 217-226
17. Ogita H., Node K., Asanuma H., Sanada S., Takashima S., Asakura M., Kitakaze M., and Hori M. Amelioration of ischemia-and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J. Cardiol. 39 (2002) 55-56
18. Ogita H., Node K., Asanuma H., Sanada S., Kim J., Takashima S., Minamino T., Hori M., and Kitakaze M. Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway. J. Cardiovasc. Pharmacol. 43 (2004) 821-829
19. Ogita H., Node K., Liao Y., Ishikura F., Beppu S., Asanuma H., Sanada S., Takashima S., Minamino T., Hori M., and Kitakaze M. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43 (2004) 237-242
20. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
21. Shibata E.F., Drury T., Refsum H., Aldrete V., and Giles W. Contributions of a transient outward current to repolarization in human atrium. Am. J. Physiol. 257 (1989) H1773-H1781
22. Simoncini T., and Genazzani A.R. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J. Clin. Endocrinol. Metab. 85 (2000) 2966-2969
23. Simoncini T., Genazzani A.R., and Liao J.K. Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105 (2002) 1368-1373
24. 2+ channels. Stroke 35 (2004) 1709-1714
25. Van Wagoner D.R. Pharmacologic relevance of K(+) channel remodeling in atrial fibrillation. J. Mol. Cell. Cardiol. 32 (2000) 1763-1766
26. Van Wagoner D.R., and Nerbonne J.M. Molecular basis of electrical remodeling in atrial fibrillation. J. Mol. Cell. Cardiol. 32 (2000) 1101-1117
27. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S., and Anderson P.W. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279 (1998) 1445-1451
28. Wenger N.K. Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women. Diabetes Obes. Metab. 4 (2002) 166-176